Literature DB >> 12608935

Effect of 2 years of cortisol normalization on the impaired bone mass and turnover in adolescent and adult patients with Cushing's disease: a prospective study.

Carolina Di Somma1, Rosario Pivonello, Sandro Loche, Antongiulio Faggiano, Michele Klain, Marco Salvatore, Gaetano Lombardi, Annamaria Colao.   

Abstract

BACKGROUND: Osteoporosis is a frequent, severe and often underestimated consequence of long-term hypercortisolism, often presenting as bone fracture.
OBJECTIVE: This prospective study was designed to evaluate whether the abnormalities of bone mass and turnover can be similarly reversed in adolescent and adult patients with Cushing's disease, after correction of hypercortisolism. PATIENTS AND METHODS: Bone mineral density (BMD) at lumbar spine, serum osteocalcin (OC) and urinary cross-linked N-telopeptides of type I collagen (Ntx) levels were measured at diagnosis and 2 years after cure of Cushing's disease (CD) in six patients with childhood-onset and nine with adulthood-onset disease. Fifteen age-, sex- and body mass index (BMI)-matched healthy subjects served as controls.
RESULTS: At diagnosis, BMD Z scores at lumbar spine and OC levels were lower (2.3 +/- 0.1 vs.-0.2 +/- 0.01; P < 0.01 and 1.6 +/- 0.1 vs. 9.6 +/- 1.2; P < 0.01 respectively) while urinary Ntx levels were significantly higher (139.9 +/- 6.1 vs. 82.0 +/- 1.6; P < 0.01) in CD patients than in controls. Among CD patients, similar values of Z scores (-2.4 +/- 0.3 vs.-2.2 +/- 0.1, P = 0.4) and OC levels (1.7 +/- 0.2 vs. 1.6 +/- 0.2, P = 0.6) were observed in adolescent and adults patients, whereas urinary Ntx levels were significantly higher (159.7 +/- 7.9 vs. 125.9 +/- 3.3, P < 0.001) in the former than in the latter group. Two years after remission from hypercortisolism, OC levels (P < 0.001) and lumbar BMD Z scores (-2.2 +/- 0.3, P < 0.05; and -1.9 +/- 0.2; P < 0.01, respectively) increased significantly, while urinary Ntx levels reduced significantly (P < 0.001) in both adolescent and adult patients. However, biochemical markers and Z scores of BMD remained significantly suppressed compared to controls.
CONCLUSIONS: Bone impairment in childhood- and adulthood-onset Cushing's disease patients can be partly, but not completely, reversed 2 years after normalization of cortisol levels. Longer recovery times or additive therapeutic approaches are necessary to maximize peak bone mass in children and restore bone mass in adults with Cushing's disease.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12608935     DOI: 10.1046/j.1365-2265.2003.01713.x

Source DB:  PubMed          Journal:  Clin Endocrinol (Oxf)        ISSN: 0300-0664            Impact factor:   3.478


  30 in total

1.  Beneficial treatment with risedronate in long-term survivors after allogeneic stem cell transplantation for hematological malignancies.

Authors:  L Tauchmanovà; C Selleri; M Esposito; C Di Somma; F Orio; G Bifulco; S Palomba; G Lombardi; B Rotoli; A Colao
Journal:  Osteoporos Int       Date:  2003-09-30       Impact factor: 4.507

Review 2.  Managing Cushing's disease: the state of the art.

Authors:  Annamaria Colao; Marco Boscaro; Diego Ferone; Felipe F Casanueva
Journal:  Endocrine       Date:  2014-01-11       Impact factor: 3.633

Review 3.  Cushing's syndrome and bone.

Authors:  Tatiana Mancini; Mauro Doga; Gherardo Mazziotti; Andrea Giustina
Journal:  Pituitary       Date:  2004       Impact factor: 4.107

4.  Variable deficits of bone mineral despite chronic glucocorticoid therapy in pediatric patients with inflammatory diseases: a Glaser Pediatric Research Network study.

Authors:  Emily von Scheven; Catherine M Gordon; David Wypij; Marcia Wertz; Kerry T Gallagher; Laura Bachrach
Journal:  J Pediatr Endocrinol Metab       Date:  2006-06       Impact factor: 1.634

5.  Bone mineral density at diagnosis and following successful treatment of pediatric Cushing's disease.

Authors:  S Scommegna; J P Greening; H L Storr; K M Davies; N J Shaw; J P Monson; A B Grossman; M O Savage
Journal:  J Endocrinol Invest       Date:  2005-03       Impact factor: 4.256

6.  Bone turnover in patients with endogenous Cushing's syndrome before and after successful treatment.

Authors:  A Szappanos; J Toke; D Lippai; A Patócs; P Igaz; N Szücs; L Füto; E Gláz; K Rácz; M Tóth
Journal:  Osteoporos Int       Date:  2009-06-10       Impact factor: 4.507

7.  Treatment of Cushing disease: overview and recent findings.

Authors:  Tatiana Mancini; Teresa Porcelli; Andrea Giustina
Journal:  Ther Clin Risk Manag       Date:  2010-10-21       Impact factor: 2.423

8.  Improved quality of life after bilateral laparoscopic adrenalectomy for Cushing's disease: a 10-year experience.

Authors:  Sarah K Thompson; Amanda V Hayman; William H Ludlam; Clifford W Deveney; D Lynn Loriaux; Brett C Sheppard
Journal:  Ann Surg       Date:  2007-05       Impact factor: 12.969

9.  Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline.

Authors:  Lynnette K Nieman; Beverly M K Biller; James W Findling; M Hassan Murad; John Newell-Price; Martin O Savage; Antoine Tabarin
Journal:  J Clin Endocrinol Metab       Date:  2015-07-29       Impact factor: 5.958

Review 10.  Cushing's disease: the burden of illness.

Authors:  Rosario Pivonello; Maria Cristina De Martino; Monica De Leo; Chiara Simeoli; Annamaria Colao
Journal:  Endocrine       Date:  2016-05-17       Impact factor: 3.633

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.